Benchmark lowered the firm’s price target on Agilon Health (AGL) to $1.50 from $4 and keeps a Buy rating on the shares. The stock was “cut roughly in half yesterday” after Agilon reported a wide Q2 miss, suspended FY25 guidance, and announced that CEO Steven Sell had stepped down, the analyst noted. Given the “positive trends still in place for 2026,” and with the stock now selling just slightly above cash per share, the firm reduced its target but maintains a Buy rating.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGL:
- Agilon Health price target lowered to $1 from $4 at TD Cowen
- Agilon Health Reports Q2 2025 Results Amid Leadership Change
- Agilon Health downgraded to Neutral from Buy at Citi
- Optimistic Buy Rating for Agilon Health Amid Strategic Initiatives and Future Prospects
- Agilon Health’s Hold Rating Amid CEO Resignation and Earnings Shortfall